Delving into the Latest Updates on C.T. Development America, Inc. with Synapse

The primary purpose of this study is to assess the efficacy, tolerability and safety of RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.

开始日期2012-08-01

申办/合作机构

C.T. Development America, Inc.

NCT01639846 / Completed临床2期

A Single-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the Onset and Duration of Action of RX-10045 Ophthalmic Solution, 0.09% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis

开始日期2012-07-01

申办/合作机构

C.T. Development America, Inc.

NCT01215747 / Completed临床3期

International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis

The primary purpose of this study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA Amyloidosis.

开始日期2010-11-01

申办/合作机构

C.T. Development America, Inc.

100 项与 C.T. Development America, Inc. 相关的临床结果

登录后查看更多信息

0 项与 C.T. Development America, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 C.T. Development America, Inc. 相关的药物交易

登录后查看更多信息

100 项与 C.T. Development America, Inc. 相关的转化医学

登录后查看更多信息